The five QMM practice areas, decoded.
FDA’s Quality Management Maturity program is organised around five practice areas. Each page below explains what makes that area hard, the mechanism that actually moves it, and how SPEQ decodes it — the practice-area names are FDA facts, the framing is SPEQ synthesis.
How QMM maps to ICH Q10 & ISO 9001 →What the programme is, and what it is not
Quality Management Maturity is FDA’s attempt to describe something inspection cannot see. An inspection establishes whether an operation meets requirements on the days it is examined; it says very little about whether that operation will still be meeting them in two years, or whether it is absorbing problems quietly because raising one is expensive. Maturity is the word for that difference, and the five practice areas are how FDA has chosen to decompose it.
The decomposition is worth reading as an argument rather than as a checklist. Two of the five — Management Commitment and Employee Empowerment — are about whether the organisation hears bad news early, which is the single strongest predictor of whether anything else on the list works. Business Continuity is there because a quality system that cannot keep supplying is a patient-safety problem wearing a commercial label. Technical Excellence and an Advanced Pharmaceutical Quality System are the parts most organisations recognise, and the parts that most often sit at a higher level than the other three can support.
SPEQ does not score QMM and could not. The programme is FDA’s, its assessment protocol is FDA’s, and nothing on these pages is a rating of any organisation against it. What these pages carry is a decode: what makes each area hard in practice, the mechanism that actually moves it, and the observable behaviour that distinguishes an operation doing the work from one describing it. The practice-area names and the programme’s structure are FDA facts; the framing around them is SPEQ synthesis and is labelled as such throughout.